Literature DB >> 32196429

Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation.

Rishi Agrawal1, Anjana Yeldandi1, Hatice Savas1, Nishant D Parekh1, Pamela J Lombardi1, Eric M Hart1.   

Abstract

Pulmonary mucormycosis (PM) is an uncommon fungal infection most often seen in immunocompromised patients. The fungus grows on decaying food, soil, and animal excrement. Patients usually become infected by inhalation of spores. The most common risk factors include diabetes mellitus, hematologic malignancy, and solid organ or stem cell transplant. PM can have a nonspecific appearance at imaging. For example, early imaging may show peribronchial ground-glass opacity. Later, the disease progresses to consolidation, nodules, or masses. Because patients are usually immunocompromised, the differential diagnosis often includes invasive pulmonary aspergillosis (IPA). Various radiologic findings suggestive of PM have been identified to help differentiate it from IPA. For example, the reverse halo sign is more closely associated with PM than with IPA. The reverse halo sign is an area of ground-glass opacity surrounded by a rim of consolidation. In addition, the presence of pleural effusions and more than 10 nodules is more suggestive of PM than it is of IPA. PM can progress rapidly in neutropenic patients. Identification of the hyphae in tissue by using endobronchial or percutaneous sampling can allow differentiation from IPA and help confirm the diagnosis of mucormycosis. Because of the high mortality rate associated with PM, early identification of the disease is critical for an improved likelihood of survival. A multimodality treatment approach with antifungal agents and surgical débridement has been shown to improve outcomes. The authors review the risk factors for PM, describe its imaging appearance and disease process, and describe the treatment of the disease. ©RSNA, 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32196429     DOI: 10.1148/rg.2020190156

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  14 in total

Review 1.  Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review.

Authors:  Jing Bao; Chunyu Liu; Yongxia Dong; Yu Xu; Zhanwei Wang; Kunkun Sun; Wen Xi; Keqiang Wang; Pihua Gong; Zhancheng Gao
Journal:  Can Respir J       Date:  2022-06-02       Impact factor: 2.130

Review 2.  Imaging Approach to Pulmonary Infections in the Immunocompromised Patient.

Authors:  Shabnam Bhandari Grover; Hemal Grover; Neha Antil; Sayantan Patra; Manas Kamal Sen; Deepthi Nair
Journal:  Indian J Radiol Imaging       Date:  2022-05-27

Review 3.  CT appearance of gastrointestinal tract mucormycosis.

Authors:  Samarjit Singh Ghuman; Pendyala Sindhu; T B S Buxi; Swapnil Sheth; Anurag Yadav; Kishan Singh Rawat; Seema Sud
Journal:  Abdom Radiol (NY)       Date:  2020-11-10

4.  Characteristics of Mucormycosis in Hematological Patients and a Death Prediction Model.

Authors:  Xiaoxu Ma; Ang Li; Weijie Cao; Huiling Li; Suping Zhang; Li Li; Haizhou Xing; Wenliang Tian; Pengfei Jiao; Jiajun Chen; Qingxian Zhang; Aiguo Xu; Lihua Xing
Journal:  Front Microbiol       Date:  2021-12-15       Impact factor: 5.640

5.  Pulmonary mucormycosis mimicking lung tumour in an uncontrolled diabetic patient.

Authors:  Elham Sadat Banimostafavi; Mahdi Fakhar; Zakaria Zakariaei; Ali Sharifpour; Mostafa Soleymani
Journal:  Respirol Case Rep       Date:  2022-02-23

Review 6.  Rhino-orbito-cerebral Mucormycosis: Pictorial Review.

Authors:  Vivek Pai; Rima Sansi; Ritesh Kharche; Sridevi Chaitanya Bandili; Bhujang Pai
Journal:  Insights Imaging       Date:  2021-11-12

7.  In silico prediction and structure-based multitargeted molecular docking analysis of selected bioactive compounds against mucormycosis.

Authors:  Premnath Madanagopal; Nagarjun Ramprabhu; Rahul Jagadeesan
Journal:  Bull Natl Res Cent       Date:  2022-01-31

8.  Radiological spectrum of invasive mucormycosis in COVID-19.

Authors:  Nandini Passi; Anshu C Wadhwa; Swati Naik
Journal:  BJR Case Rep       Date:  2022-03-09

Review 9.  Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.

Authors:  Omer Sefvan Janjua; Muhammad Saad Shaikh; Muhammad Amber Fareed; Sana Mehmood Qureshi; Muhammad Ikram Khan; Danya Hashem; Muhammad Sohail Zafar
Journal:  J Fungi (Basel)       Date:  2021-12-31

10.  Rhizopus microsporus lung infection in an immunocompetent patient successfully treated with amphotericin B: A case report.

Authors:  Long Chen; Yuan Su; Xian-Zhi Xiong
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.